Skip to main content
TipRanks
Go Ultimate75% OFF

Atrium Therapeutics, Inc. (RNA) Drug Pipeline

25 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Aoc-1020Facioscapulohumeral Muscular Dystrophy 1, Fshd, Fshd1, Fshd2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Fsh Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Landouzy-Dejerine Syndrome, Facioscapulohumeral Muscular Dystrophy, Fshd - Facioscapulohumeral Muscular Dystrophy, Facioscapulohumeral Dystrophy, Facioscapulohumeral Muscular Dystrophy Type 1 (Fshd1)Phase IIIRecruitingA Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHDJun 13, 2025
Del-DesiranDm1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Disorders, Myotonia, Myotonic Dystrophy Type 1, Steinert Myotonic Dystrophy, Steinert'S DiseasePhase IIIEnrolling By InvitationGlobal Open-Label Extension Study of Del-desiran for the Treatment of DM1May 29, 2025
Aoc 1020Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy 1, Fshd, Fshd1, Fshd2, Fmd, Fmd2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophy, Facioscapulohumeral, Fsh Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, FshPhase IIEnrolling By InvitationPhase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)Aug 07, 2024―
Aoc 1001Dm1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (Dm1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy, Myotonia, SteinertPhase IIIActive Not RecruitingGlobal Study of Del-desiran for the Treatment of DM1May 08, 2024―
Aoc 1044Duchenne Muscular Dystrophy, Dmd, Duchenne, Exon 44Phase IIActive Not RecruitingPh2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 SkippingJan 26, 2024―
Aoc 1020Muscular Dystrophies, Facioscapulohumeral Muscular Dystrophy 1, Fshd, Fshd1, Fshd2, Fmd, Fmd2, Fascioscapulohumeral Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy Type 1, Fascioscapulohumeral Muscular Dystrophy Type 2, Dystrophies, Facioscapulohumeral Muscular, Dystrophy, Facioscapulohumeral Muscular, Facioscapulohumeral Muscular Dystrophy 2, Facio-Scapulo-Humeral Dystrophy, Atrophy, Facioscapulohumeral, Atrophies, Facioscapulohumeral, Facioscapulohumeral Atrophy, Muscular Dystrophy, Facioscapulohumeral, Fsh Muscular Dystrophy, Landouzy Dejerine Dystrophy, Landouzy-Dejerine Muscular Dystrophy, Dystrophies, Landouzy-Dejerine, Dystrophy, Landouzy-Dejerine, Landouzy-Dejerine Syndrome, Muscular Dystrophy, Landouzy Dejerine, Progressive Muscular Dystrophy, Fshphase1AndPhase2Active Not RecruitingPhase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)Feb 17, 2023―
Aoc 1044Duchenne Muscular Dystrophy, Exon 44phase1AndPhase2CompletedStudy of AOC 1044 in Healthy Adult Volunteers and Participants With Duchenne Muscular Dystrophy (DMD) Mutations Amenable to Exon 44 SkippingDec 06, 2022―
Aoc 1001Nervous System Diseases, Neurodegenerative Diseases, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Genetic Diseases, Inborn, Dm1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Disorders, Heredodegenerative Disorders, Nervous SystemPhase IICompletedExtension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) PatientsJul 27, 2022
Aoc 1001Dm1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (Dm1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophyphase1AndPhase2CompletedStudy of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) PatientsAug 24, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Atrium Therapeutics, Inc. (RNA) have in its pipeline
Atrium Therapeutics, Inc. RNA is currently developing the following drugs: Aoc-1020, Del-Desiran, Aoc 1020, Aoc 1001, Aoc 1044. These drug candidates are in various stages of clinical development as the company works toward FDA approval.